Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 263

1.

Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?

Morris V, Dasari A, Kopetz S.

JAMA Oncol. 2019 May 9. doi: 10.1001/jamaoncol.2019.0503. [Epub ahead of print] No abstract available.

PMID:
31070713
2.

Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Kawaguchi Y, Lillemoe HA, Panettieri E, Chun YS, Tzeng CD, Aloia TA, Kopetz S, Vauthey JN.

J Am Coll Surg. 2019 May 2. pii: S1072-7515(19)30303-5. doi: 10.1016/j.jamcollsurg.2019.04.027. [Epub ahead of print]

PMID:
31054911
3.

KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.

Liao W, Overman MJ, Boutin AT, Shang X, Zhao D, Dey P, Li J, Wang G, Lan Z, Li J, Tang M, Jiang S, Ma X, Chen P, Katkhuda R, Korphaisarn K, Chakravarti D, Chang A, Spring DJ, Chang Q, Zhang J, Maru DM, Maeda DY, Zebala JA, Kopetz S, Wang YA, DePinho RA.

Cancer Cell. 2019 Apr 15;35(4):559-572.e7. doi: 10.1016/j.ccell.2019.02.008. Epub 2019 Mar 21.

PMID:
30905761
4.

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study.

Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T, Wasan H, Desai J, Ciardiello F, Gollerkeri A, Christy-Bittel J, Maharry K, Sandor V, Schellens JHM, Kopetz S, Tabernero J.

J Clin Oncol. 2019 Jun 10;37(17):1460-1469. doi: 10.1200/JCO.18.02459. Epub 2019 Mar 20.

PMID:
30892987
5.

Clinical and molecular characterization of early-onset colorectal cancer.

Willauer AN, Liu Y, Pereira AAL, Lam M, Morris JS, Raghav KPS, Morris VK, Menter D, Broaddus R, Meric-Bernstam F, Hayes-Jordan A, Huh W, Overman MJ, Kopetz S, Loree JM.

Cancer. 2019 Jun 15;125(12):2002-2010. doi: 10.1002/cncr.31994. Epub 2019 Mar 11.

PMID:
30854646
6.

Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials.

Advani S, Kopetz S.

J Surg Oncol. 2019 Apr;119(5):642-652. doi: 10.1002/jso.25441. Epub 2019 Mar 10. Review.

PMID:
30852840
7.

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.

Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG.

J Immunother Cancer. 2019 Feb 8;7(1):37. doi: 10.1186/s40425-019-0518-z.

8.

Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS.

Wang J, Yi Y, Xiao Y, Dong L, Liang L, Teng L, Ying JM, Lu T, Liu Y, Guan Y, Pang J, Zhou L, Lu J, Zhang Z, Liu X, Liang X, Zeng X, Yi X, Zhou W, Xia X, Yang L, Zhang J, Kopetz S, Futreal PA, Wu H, Liang Z.

Mod Pathol. 2019 Feb 5. doi: 10.1038/s41379-019-0212-1. [Epub ahead of print]

PMID:
30723297
9.

Back to the Colorectal Cancer Consensus Molecular Subtype Future.

Menter DG, Davis JS, Broom BM, Overman MJ, Morris J, Kopetz S.

Curr Gastroenterol Rep. 2019 Jan 30;21(2):5. doi: 10.1007/s11894-019-0674-9. Review.

PMID:
30701321
10.

Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.

Margalit O, Mamtani R, Kopetz S, Yang YX, Lawrence YR, Abu-Gazala S, Reiss KA, Golan T, Halpern N, Aderka D, Giantonio B, Shacham-Shmueli E, Boursi B.

Oncologist. 2019 Jan 29. pii: theoncologist.2018-0333. doi: 10.1634/theoncologist.2018-0333. [Epub ahead of print]

PMID:
30696723
11.

Real-Time Interrogation of Aspirin Reactivity, Biochemistry, and Biodistribution by Hyperpolarized Magnetic Resonance Spectroscopy.

Zacharias NM, Ornelas A, Lee J, Hu J, Davis JS, Uddin N, Pudakalakatti S, Menter DG, Karam JA, Wood CG, Hawk ET, Kopetz S, Vilar E, Bhattacharya PK, Millward SW.

Angew Chem Int Ed Engl. 2019 Mar 22;58(13):4179-4183. doi: 10.1002/anie.201812759. Epub 2019 Feb 20.

12.

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.

Varkaris A, Katsiampoura A, Davis JS, Shah N, Lam M, Frias RL, Ivan C, Shimizu M, Morris J, Menter D, Overman M, Tran H, Heymach J, Chun YS, Vauthey JN, Calin G, Kopetz S.

Br J Cancer. 2019 Feb;120(3):340-345. doi: 10.1038/s41416-018-0360-y. Epub 2019 Jan 14.

PMID:
30636774
13.

New therapies and insights into the changing landscape of colorectal cancer.

Kopetz S.

Nat Rev Gastroenterol Hepatol. 2019 Feb;16(2):79-80. doi: 10.1038/s41575-018-0100-z. No abstract available.

PMID:
30575801
14.

Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge.

Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S.

Ann Oncol. 2019 Feb 1;30(2):243-249. doi: 10.1093/annonc/mdy509.

PMID:
30462160
15.

Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.

Chang K, Willis JA, Reumers J, Taggart MW, San Lucas FA, Thirumurthi S, Kanth P, Delker DA, Hagedorn CH, Lynch PM, Ellis LM, Hawk ET, Scheet PA, Kopetz S, Arts J, Guinney J, Dienstmann R, Vilar E.

Ann Oncol. 2018 Oct 1;29(10):2061-2067. doi: 10.1093/annonc/mdy337.

PMID:
30412224
16.

Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies.

Dasari A, Grothey A, Kopetz S.

J Clin Oncol. 2018 Oct 30:JCO2018789032. doi: 10.1200/JCO.2018.78.9032. [Epub ahead of print] No abstract available.

PMID:
30376428
17.

TMEM9 promotes intestinal tumorigenesis through vacuolar-ATPase-activated Wnt/β-catenin signalling.

Jung YS, Jun S, Kim MJ, Lee SH, Suh HN, Lien EM, Jung HY, Lee S, Zhang J, Yang JI, Ji H, Wu JY, Wang W, Miller RK, Chen J, McCrea PD, Kopetz S, Park JI.

Nat Cell Biol. 2018 Dec;20(12):1421-1433. doi: 10.1038/s41556-018-0219-8. Epub 2018 Oct 29.

18.

DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway.

Adam L, San Lucas FA, Fowler R, Yu Y, Wu W, Liu Y, Wang H, Menter D, Tetzlaff MT, Ensor J Jr, Manyam G, Arold ST, Huff C, Kopetz S, Scheet P, Overman MJ.

Clin Cancer Res. 2019 Jan 15;25(2):641-651. doi: 10.1158/1078-0432.CCR-18-1480. Epub 2018 Oct 23.

PMID:
30352910
19.

Prognostic Implications of Mucinous Differentiation in Metastatic Colorectal Carcinoma Can Be Explained by Distinct Molecular and Clinicopathologic Characteristics.

Khan M, Loree JM, Advani SM, Ning J, Li W, Pereira AAL, Lam M, Raghav K, Morris VK, Broaddus R, Maru D, Overman MJ, Kopetz S.

Clin Colorectal Cancer. 2018 Dec;17(4):e699-e709. doi: 10.1016/j.clcc.2018.07.005. Epub 2018 Jul 17.

20.

Loss of muscle mass during preoperative chemotherapy as a prognosticator for poor survival in patients with colorectal liver metastases.

Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Aloia TA, Conrad C.

Surgery. 2019 Feb;165(2):329-336. doi: 10.1016/j.surg.2018.07.031. Epub 2018 Sep 6.

PMID:
30197278
21.

Bioactive lipid metabolism in platelet "first responder" and cancer biology.

Kanikarla-Marie P, Kopetz S, Hawk ET, Millward SW, Sood AK, Gresele P, Overman M, Honn K, Menter DG.

Cancer Metastasis Rev. 2018 Sep;37(2-3):439-454. doi: 10.1007/s10555-018-9755-8. Review.

PMID:
30112590
22.

Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.

Advani SM, Advani P, DeSantis SM, Brown D, VonVille HM, Lam M, Loree JM, Mehrvarz Sarshekeh A, Bressler J, Lopez DS, Daniel CR, Swartz MD, Kopetz S.

Transl Oncol. 2018 Oct;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. Epub 2018 Jul 30.

23.

Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer.

Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S.

Ann Oncol. 2019 Mar 1;30(3):495. doi: 10.1093/annonc/mdy221. No abstract available.

24.

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer.

Mehrvarz Sarshekeh A, Xiong HQ, Iizuka K, Hochster HS, Kopetz S.

Invest New Drugs. 2018 Oct;36(5):895-902. doi: 10.1007/s10637-018-0615-8. Epub 2018 Jun 13.

PMID:
29948357
25.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

Goey KKH, Sørbye H, Glimelius B, Adams RA, André T, Arnold D, Berlin JD, Bodoky G, de Gramont A, Díaz-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M.

Eur J Cancer. 2018 Sep;100:35-45. doi: 10.1016/j.ejca.2018.05.010. Epub 2018 Jun 22.

PMID:
29936065
26.

How should BRAF V600E-mutated colorectal cancer be treated?

Kopetz S.

Clin Adv Hematol Oncol. 2018 May;16(5):333-335. No abstract available.

PMID:
29851929
27.

RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases.

Okuno M, Goumard C, Kopetz S, Vega EA, Joechle K, Mizuno T, Omichi K, Tzeng CD, Chun YS, Vauthey JN, Conrad C.

Ann Surg Oncol. 2018 Aug;25(8):2457-2466. doi: 10.1245/s10434-018-6517-3. Epub 2018 May 21.

PMID:
29786130
28.

Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy.

Kanikarla-Marie P, Lam M, Sorokin AV, Overman MJ, Kopetz S, Menter DG.

Front Oncol. 2018 Apr 20;8:107. doi: 10.3389/fonc.2018.00107. eCollection 2018. Review.

29.

Untying the gordion knot of targeting MET in cancer.

Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D.

Cancer Treat Rev. 2018 May;66:95-103. doi: 10.1016/j.ctrv.2018.04.008. Epub 2018 Apr 26. Review.

PMID:
29730462
30.

Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer.

Loree JM, Bailey AM, Johnson AM, Yu Y, Wu W, Bristow CA, Davis JS, Shaw KR, Broaddus R, Banks KC, Lanman RB, Meric-Bernstam F, Overman MJ, Kopetz S, Raghav K.

J Natl Cancer Inst. 2018 Dec 1;110(12):1409-1417. doi: 10.1093/jnci/djy067.

31.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

32.

Correction to: Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Apr 23;19(5):25. doi: 10.1007/s11864-018-0537-x.

PMID:
29687230
33.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy.

Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, Pant S.

J Immunother. 2018 Jul/Aug;41(6):284-291. doi: 10.1097/CJI.0000000000000222.

PMID:
29668571
34.

Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules.

Sankhala K, Takimoto CH, Mita AC, Xiong H, Rodón J, Mehrvarz Sarshekeh A, Burns K, Iizuka K, Kopetz S.

Invest New Drugs. 2019 Feb;37(1):76-86. doi: 10.1007/s10637-018-0602-0. Epub 2018 Apr 18.

PMID:
29667134
35.

Prognostic impact of perihepatic lymph node metastases in patients with resectable colorectal liver metastases.

Okuno M, Goumard C, Mizuno T, Kopetz S, Omichi K, Tzeng CD, Chun YS, Lee JE, Vauthey JN, Conrad C.

Br J Surg. 2018 Aug;105(9):1200-1209. doi: 10.1002/bjs.10822. Epub 2018 Apr 17.

PMID:
29664996
36.

Biomarkers in colorectal liver metastases.

Yamashita S, Chun YS, Kopetz SE, Vauthey JN.

Br J Surg. 2018 May;105(6):618-627. doi: 10.1002/bjs.10834. Epub 2018 Mar 26. Review.

PMID:
29579319
37.

SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.

Mizuno T, Cloyd JM, Vicente D, Omichi K, Chun YS, Kopetz SE, Maru D, Conrad C, Tzeng CD, Wei SH, Aloia TA, Vauthey JN.

Eur J Surg Oncol. 2018 May;44(5):684-692. doi: 10.1016/j.ejso.2018.02.247. Epub 2018 Mar 7.

PMID:
29551247
38.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.

Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R.

Oncotarget. 2017 Oct 24;9(12):10259-10271. doi: 10.18632/oncotarget.21982. eCollection 2018 Feb 13.

39.

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.

Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, Yamada Y, Becerra C, Kopetz S, Wang X, Goel A.

Clin Cancer Res. 2018 Aug 15;24(16):3867-3877. doi: 10.1158/1078-0432.CCR-17-3236. Epub 2018 Mar 7.

40.

Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer.

Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S.

Curr Treat Options Oncol. 2018 Feb 27;19(2):11. doi: 10.1007/s11864-018-0524-2. Review. Erratum in: Curr Treat Options Oncol. 2018 Apr 23;19(5):25.

PMID:
29488033
41.

Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer.

Mehrvarz Sarshekeh A, Overman MJ, Kopetz S.

Future Oncol. 2018 Aug;14(18):1869-1874. doi: 10.2217/fon-2017-0696. Epub 2018 Feb 23. Review.

PMID:
29473436
42.

Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.

Montagut C, Argilés G, Ciardiello F, Poulsen TT, Dienstmann R, Kragh M, Kopetz S, Lindsted T, Ding C, Vidal J, Clausell-Tormos J, Siravegna G, Sánchez-Martín FJ, Koefoed K, Pedersen MW, Grandal MM, Dvorkin M, Wyrwicz L, Rovira A, Cubillo A, Salazar R, Desseigne F, Nadal C, Albanell J, Zagonel V, Siena S, Fumi G, Rospo G, Nadler P, Horak ID, Bardelli A, Tabernero J.

JAMA Oncol. 2018 Apr 12;4(4):e175245. doi: 10.1001/jamaoncol.2017.5245. Epub 2018 Apr 12. Erratum in: JAMA Oncol. 2019 May 1;5(5):745.

43.

Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases.

Odisio BC, Yamashita S, Huang SY, Kopetz SE, Ahrar K, Mizuno T, Conrad C, Aloia TA, Chun YS, Gupta S, Vauthey JN.

J Vasc Interv Radiol. 2018 Mar;29(3):395-403.e1. doi: 10.1016/j.jvir.2017.10.026. Epub 2018 Feb 1.

44.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

PMID:
29355075
45.

The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.

Overman MJ, Ferrarotto R, Raghav K, George B, Qiao W, Machado KK, Saltz LB, Mazard T, Vauthey JN, Hoff PM, Hobbs B, Loyer EM, Kopetz S.

J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. doi: 10.1093/jnci/djx288.

PMID:
29346573
46.

Arginine methylation of EGFR: a new biomarker for predicting resistance to anti-EGFR treatment.

Korphaisarn K, Chou CK, Xia WY, Clarke CN, Katkhuda R, Davis JS, Raghav KP, Liao HW, Wu JY, Menter DG, Maru DM, Hung MC, Kopetz S.

Am J Cancer Res. 2017 Dec 1;7(12):2587-2599. eCollection 2017.

47.

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Strickler JH, Loree JM, Ahronian LG, Parikh AR, Niedzwiecki D, Pereira AAL, McKinney M, Korn WM, Atreya CE, Banks KC, Nagy RJ, Meric-Bernstam F, Lanman RB, Talasaz A, Tsigelny IF, Corcoran RB, Kopetz S.

Cancer Discov. 2018 Feb;8(2):164-173. doi: 10.1158/2159-8290.CD-17-1009. Epub 2017 Dec 1.

48.

Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes.

Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S.

Clin Cancer Res. 2018 Mar 1;24(5):1062-1072. doi: 10.1158/1078-0432.CCR-17-2484. Epub 2017 Nov 27.

49.

Integrated safety summary for trifluridine/tipiracil (TAS-102).

Falcone A, Ohtsu A, Van Cutsem E, Mayer RJ, Buscaglia M, Bendell JC, Kopetz S, Bebeau P, Yoshino T.

Anticancer Drugs. 2018 Jan;29(1):89-96. doi: 10.1097/CAD.0000000000000554.

PMID:
29176395
50.

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.

Yoshino T, Arnold D, Taniguchi H, Pentheroudakis G, Yamazaki K, Xu RH, Kim TW, Ismail F, Tan IB, Yeh KH, Grothey A, Zhang S, Ahn JB, Mastura MY, Chong D, Chen LT, Kopetz S, Eguchi-Nakajima T, Ebi H, Ohtsu A, Cervantes A, Muro K, Tabernero J, Minami H, Ciardiello F, Douillard JY.

Ann Oncol. 2018 Jan 1;29(1):44-70. doi: 10.1093/annonc/mdx738.

PMID:
29155929

Supplemental Content

Loading ...
Support Center